QuesadaJ.R., SwansonD.A., GuttermanJ.U.Phase II study of interferon alfa in metastatic renal carcinoma.A progress report. J Clin Oncology1985; 3: 1986–92.
2.
EinzingA.L., KrownS.E., OettgenH.F.Recombinant leucocyte A interferon (rIFN-α) in renal cell carcinoma (RCC).Proc Am Soc Clin Oncol1984; 3: 54.
3.
FossaS.D., De GavisS.T.Further experience with recombinant interferon alpha-2a with vinblastin in metastatic renal cell carcinoma. A progress report.Int J Cancer1987; suppl. 1: 36–40.
4.
GattaG.L., FranceschiT., BassetoM.A.Phase I/II trial of recombinant alpha-2 interferon (IFN) and vinblastine in metastatic renal cancer (MRCC).Proc Amer Soc Clin Oncol1986: 110, abstract 427.
5.
SellaA., FinyL., AmatoR.Interferon-α (IFN-α) combined with 5-fluorouracil (5-FU) is an active regimen in metastatic renal cell cancer (RCC). Abstracts, Fourth International Congress on Anti-Cancer Chemotherapy. Paris-France, 1993.
6.
JohnstonM.I., TorrenceP.F.The role of interferon induced proteins, double-stranded RNA and 2'5’ oligoadenylate in the interferon-mediated inhibition of viral translation. In: FriedmanR.M. ed. Interferon, vol. 3. Amsterdam: Elsevier, 1984; 177–298.
7.
SchattnerA., MerlinG., WallachD.Monitoring of interferon therapy by assay of (2'-5’) oligo-isoadenylate synthetase in human peripheral white blood cells.J Interferon Res1981; 1: 587–94.
8.
MerrittJ.A., MeltzerD.M., BallL.A.2'5'A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.Prog Clin Biol Res1985; 202: 423–30.
9.
LodemanE., KornhuberB., GereinV.2'5’ oligo (A) synthetase as a monitor of interferon action in juvenile laryngeal papillomatosis.J Interferon Res1984; 4: 283–90.
10.
VakalikosJ., PeftulidisS., DimasisN.A new approach to monitor patients with renal cell carcinoma treated with IFN-α.Tumor Marker Oncology1990; 5: 101–6.
11.
VakalikosJ., DimasisN., BoutisL.Combined treatment of advanced renal cell carcinoma and monitoring of the patients with two different parameters.Acta Urologica Italica1993; 2: 91–4.
